Lyell Immunopharma, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Lyell Immunopharma, Inc. (LYEL), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are LYEL insiders buying or selling?
In the last 12 months, Lyell Immunopharma, Inc. insiders reported 2 open-market purchases ($25.0M) and 28 sales ($608.2K) — net buying of $24.4M. Since June 2021, Trabud has recorded 45 Form 4 filings for LYEL: 8 buys ($25.7M) and 37 sells ($812.8K).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $12.5M by ARCH Venture Partners IX, LLC (10% Owner) on Mar 9, 2026. SEC ↗
- The most recent open-market purchase was reported on Mar 9, 2026 (7 months ago).
Key Statistics (June 2021 – Oct 13, 2026)
Total Form 4 filings
45
SEC EDGAR
Insider filers
14
Insider buys (8)
$25.7M
Insider sells (37)
$812.8K
Insider sentiment
Net buyingNet insider flow of $24.9M in net buying since June 2021, and $24.4M in net buying over the last 12 months.
Recent LYEL insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 13, 2026 | Jarrad Mattieu Aguirre | Chief Medical Officer | Sale | 422 | $8.63 | $3.6K | SEC ↗ |
| Sep 10, 2026 | David Shook | Chief Medical Officer | Sale | 500 | $12.70 | $6.3K | SEC ↗ |
| Aug 25, 2026 | Lynn Seely | President and CEO | Sale | 9.6K | $15.54 | $149.0K | SEC ↗ |
| Aug 25, 2026 | Stephen J. Hill | Chief Operating Officer | Sale | 989 | $15.54 | $15.4K | SEC ↗ |
| Aug 25, 2026 | Gary K. Lee | Chief Scientific Officer | Sale | 1.5K | $15.54 | $22.6K | SEC ↗ |
| Aug 11, 2026 | Veronica Sanchez Bulis | VP, Corporate Controller | Sale | 621 | $14.34 | $8.9K | SEC ↗ |
| Aug 11, 2026 | Gary K. Lee | Chief Scientific Officer | Sale | 131 | $14.34 | $1.9K | SEC ↗ |
| Aug 11, 2026 | Stephen J. Hill | Chief Operating Officer | Sale | 89 | $14.34 | $1.3K | SEC ↗ |
| Aug 11, 2026 | Lynn Seely | President and CEO | Sale | 390 | $14.34 | $5.6K | SEC ↗ |
| Jul 20, 2026 | Innovative Cellular Therapeutics Holdings Ltd | 10% Owner | Sale | 10 | $13.70 | $137 | SEC ↗ |
| Jul 18, 2026 | Innovative Cellular Therapeutics Holdings Ltd | 10% Owner | Sale | 10 | $13.73 | $137.3 | SEC ↗ |
| Jun 15, 2026 | Lynn Seely | President and CEO | Sale | 388 | $18.91 | $7.3K | SEC ↗ |
| Jun 15, 2026 | Gary K. Lee | Chief Scientific Officer | Sale | 130 | $18.92 | $2.5K | SEC ↗ |
| Jun 15, 2026 | Stephen J. Hill | Chief Operating Officer | Sale | 89 | $18.92 | $1.7K | SEC ↗ |
| Jun 15, 2026 | Veronica Sanchez Bulis | VP, Corporate Controller | Sale | 217 | $18.91 | $4.1K | SEC ↗ |
| Jun 11, 2026 | David Shook | Chief Medical Officer | Sale | 2.0K | $12.64 | $25.0K | SEC ↗ |
| Mar 9, 2026 | ARCH Venture Partners IX, LLC | 10% Owner | Purchase | 488.1K | $25.61 | $12.5M | SEC ↗ |
| Mar 9, 2026 | Keith Crandell | 10% Owner | Purchase | 488.1K | $25.61 | $12.5M | SEC ↗ |
| Feb 13, 2026 | Lynn Seely | President and CEO | Sale | 7.5K | $23.39 | $174.4K | SEC ↗ |
| Feb 13, 2026 | Stephen J. Hill | Chief Operating Officer | Sale | 1.2K | $23.39 | $28.9K | SEC ↗ |
| Feb 13, 2026 | Gary K. Lee | Chief Scientific Officer | Sale | 1.7K | $23.39 | $39.1K | SEC ↗ |
| Feb 12, 2026 | Stephen J. Hill | Chief Operating Officer | Sale | 109 | $23.12 | $2.5K | SEC ↗ |
| Feb 12, 2026 | Gary K. Lee | Chief Scientific Officer | Sale | 147 | $23.12 | $3.4K | SEC ↗ |
| Feb 12, 2026 | Lynn Seely | President and CEO | Sale | 438 | $23.12 | $10.1K | SEC ↗ |
| Feb 12, 2026 | Veronica Sanchez Bulis | VP, Corporate Controller | Sale | 254 | $23.12 | $5.9K | SEC ↗ |
Showing the 25 most recent of 45 Form 4 filings for Lyell Immunopharma, Inc..
Most active LYEL insiders
- Lynn Seely9 filings
- Gary K. Lee8 filings
- Stephen J. Hill8 filings
- Veronica Sanchez Bulis5 filings
- Charles W. Newton3 filings
Ask anything about LYEL insider activity
Use Trabud's AI agent to query Lyell Immunopharma, Inc.'s Form 4 history in plain English — "Show me LYEL CEO purchases this year" or compare it against any other ticker.
Open the AI agentLYEL insider trading FAQ
Are Lyell Immunopharma, Inc. insiders buying or selling?
In the last 12 months, Lyell Immunopharma, Inc. insiders reported 2 open-market purchases ($25.0M) and 28 sales ($608.2K) — net buying of $24.4M. Since June 2021, Trabud has recorded 45 Form 4 filings for LYEL: 8 buys ($25.7M) and 37 sells ($812.8K). Over the full record that is net buying of $24.9M.
How many insiders trade LYEL stock?
14 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Lyell Immunopharma, Inc.. The most recent filing was accepted on Oct 13, 2026.
Where does Trabud get LYEL insider trading data?
All LYEL insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.